Engel Law PLLC is investigating whether fair value to Revolution Medicines, Inc. (NASDAQ: RVMD) shareholders will result from the proposed acquisition of EQRx, Inc. by Revolution, pursuant to which EQRx stockholders will receive the number of shares of Revolution common stock equal to the sum of 7,692,308 Revolution Medicines shares (determined as $200 million divided by $26.00 per share) plus a number of shares equal to $870 million divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines share price measured in close proximity to the stockholder vote.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.